Autologe hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen: Aktuelle Indikationen und Wirkungsweise, ein Review der EBMT Autoimmune Diseases Working Party (ADWP)
Standard
Autologe hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen: Aktuelle Indikationen und Wirkungsweise, ein Review der EBMT Autoimmune Diseases Working Party (ADWP). / Alexander, T; Badoglio, M; Henes, J; Heesen, C; Arnold, R; Radbruch, A; Snowden, J A; Hiepe, F.
In: Z RHEUMATOL, Vol. 79, No. 5, 06.2020, p. 419-428.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autologe hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen: Aktuelle Indikationen und Wirkungsweise, ein Review der EBMT Autoimmune Diseases Working Party (ADWP)
AU - Alexander, T
AU - Badoglio, M
AU - Henes, J
AU - Heesen, C
AU - Arnold, R
AU - Radbruch, A
AU - Snowden, J A
AU - Hiepe, F
PY - 2020/6
Y1 - 2020/6
N2 - The recent introduction of biologic and targeted synthetic disease-modifying drugs has led to more specificity in the treatment of autoimmune diseases; however, they require continuous or intermittent administration, are associated with cumulative risks for side effects, result in high costs and provide no cure. In contrast, high-dose chemotherapy followed by transplantation of autologous hematopoietic stem cells (AHSCT) has been demonstrated to induce clinical remission in various autoimmune diseases that can persist over many years without continued maintenance therapy. The principle behind AHSCT is an elimination of important components of the autoreactive immunological memory with subsequent regeneration of the complete immune system. Several studies have indicated that such an immune reset is associated with fundamental changes in the immune repertoire leading to an induction of tolerance against self-antigens. This article presents the current indications of AHSCT for autoimmune diseases based on the registry data of the European Society of Blood and Marrow Transplantation (EBMT) and discusses the results from mechanistic studies, which provide detailed insights into the mode of action of this treatment.
AB - The recent introduction of biologic and targeted synthetic disease-modifying drugs has led to more specificity in the treatment of autoimmune diseases; however, they require continuous or intermittent administration, are associated with cumulative risks for side effects, result in high costs and provide no cure. In contrast, high-dose chemotherapy followed by transplantation of autologous hematopoietic stem cells (AHSCT) has been demonstrated to induce clinical remission in various autoimmune diseases that can persist over many years without continued maintenance therapy. The principle behind AHSCT is an elimination of important components of the autoreactive immunological memory with subsequent regeneration of the complete immune system. Several studies have indicated that such an immune reset is associated with fundamental changes in the immune repertoire leading to an induction of tolerance against self-antigens. This article presents the current indications of AHSCT for autoimmune diseases based on the registry data of the European Society of Blood and Marrow Transplantation (EBMT) and discusses the results from mechanistic studies, which provide detailed insights into the mode of action of this treatment.
U2 - 10.1007/s00393-020-00795-2
DO - 10.1007/s00393-020-00795-2
M3 - SCORING: Review
C2 - 32356079
VL - 79
SP - 419
EP - 428
JO - Z RHEUMATOL
JF - Z RHEUMATOL
SN - 0340-1855
IS - 5
ER -
